Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Medmix AGMDMXF 66 EV-to-EBIT is 36.50 as of Jul. 31, 2026, which is 30% below its 10-year median of 52.06. GuruFocus rates MDMXF with a GF Score™ of 66/100 and a GF Value™ of $18.45. The stock has 6 warning signs investors should review. Among 2,378 Industrial Products companies, Medmix AG ranks worse than 73.42% on this metric.
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
Medmix AG's Enterprise Value for the quarter that ended in Jun. 2026 was $977.8 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Medmix AG's EBIT for the trailing twelve months (TTM) ended in Jun. 2026 was $19.0 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Medmix AG EV-to-EBIT Related Terms
Medmix AG EV-to-EBIT Historical Data
* Premium members only.
The historical data trend for Medmix AG's EV-to-EBIT can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Specialty Industrial Machinery subindustry, Medmix AG's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Medmix AG EV-to-EBIT vs Industrial Products Industry
For the Industrial Products industry and Industrials sector, Medmix AG's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Medmix AG's EV-to-EBIT falls into.
Medmix AG's current Enterprise Value is $694.9 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Medmix AG's EBIT for the trailing twelve months (TTM) ended in Jun. 2026 was $19.0 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Medmix AG (MDMXF) has a EV-to-EBIT of 36.50 as of Jul. 31, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Medmix AG and its competitors. This is 30% below median its historical median of 52.06. Over the past decade, Medmix AG's EV-to-EBIT has ranged from 13.03 to 139.74. According to the industry distribution chart, Medmix AG ranks #1746 out of 2378 companies in the Industrial Products industry, placing it in the top 73.4%.
Is Medmix AG's EV-to-EBIT too high?
Medmix AG's current EV-to-EBIT of 36.50 is 30% below median its 10-year median of 52.06. Over the past 10 years, this metric has ranged from a low of 13.03 to a high of 139.74. The Industrial Products industry median EV-to-EBIT is 18.94. Medmix AG's value of 36.50 is 92.8% above this industry median. Based on the distribution chart, Medmix AG ranks #1746 out of 2378 companies in the Industrial Products industry, which is below the industry midpoint. Overall, Medmix AG has a GF Score™ of 66/100, reflecting its overall financial health beyond just this single metric.
How does Medmix AG's EV-to-EBIT compare to GEV and ETN?
According to the Industrial Products industry distribution chart, Medmix AG ranks #1746 out of 2378 companies for EV-to-EBIT. This places Medmix AG in the lower half of its industry. The industry median EV-to-EBIT is 18.94. Medmix AG's value of 36.50 is 92.8% above this benchmark. Historically, Medmix AG's own EV-to-EBIT has ranged from 13.03 to 139.74 over the past decade. While the company's 10-year median is 52.06 vs. the industry median of 18.94, Medmix AG has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for an Industrial Products company?
The median EV-to-EBIT among Industrial Products companies is 18.94, based on 2,378 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Medmix AG's current EV-to-EBIT of 36.50 is 92.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Medmix AG and its competitors. For the Industrial Products industry, the median EV-to-EBIT is 18.94 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Medmix AG's current EV-to-EBIT is 36.50, which is 30% below median its own 10-year median of 52.06. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Medmix AG stock overvalued right now?
Medmix AG (MDMXF) has a current EV-to-EBIT of 36.50. The stock's GF Value™ is $18.45, compared to a current price of $17.40 — trading 5.7% below its estimated fair value. The current EV-to-EBIT is 36.50, which is 30% below median its 10-year median of 52.06 and 92.8% above the Industrial Products industry median of 18.94. Medmix AG's overall GF Score™ is 66/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For Medmix AG (MDMXF), the current EV-to-EBIT is 36.50 as of Jul. 31, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Medmix AG (MDMXF) Overvalued in 2026?
Based on GuruFocus' analysis, Medmix AG stock appears to be undervalued.
The current stock price of $17.40 is trading 5.7% below its estimated GF Value™ of $18.45.
Key valuation signals for MDMXF:
EV-to-EBIT: 36.50 (30% below median its 10-year median of 52.06)
GF Value™: $18.45 vs. price of $17.40 (5.7% below fair value)
Industry Position: 92.8% above the Industrial Products median (#1746 of 2378)
No single metric tells the full story. See the MDMXF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Medmix AG designs and produces high-precision delivery devices for the healthcare, consumer and industrial segments. Its segments are Healthcare, Consumer & Industrial, and Others. The Healthcare segment focuses on delivery devices for the drug delivery, surgery, and dental markets, including injection pens for subcutaneous drug delivery, surgical delivery devices, and mixing and delivery systems for the dental consumable industry. The Consumer & Industrial segment focuses on delivery devices used for industrial applications such as adhesives in construction, electronics, automotive, and aerospace, as well as consumer markets such as beauty and microbrush applications. The company operates in Europe, the Middle East and Africa, the Americas, and Asia-Pacific.
66GF Score
Get the complete analysis for MDMXF
EV-to-EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MDMXF has been successfully added to your 
